Syngeneic models provide a platform of complete immune system to test the efficacy of immune-oncology drugs and treatment. About 12 mouse tumor models can be selected to test various checkpoint inhibitors or other immune-oncological treatments. In addition to providing standard drug response curves, FACS, ELISA and IHC analysis of TILs are also available.
| Model | Cancer Type |
| MC38 | Colon cancer |
| CT26 | colon cancer |
| B16F10 | Melanoma |
| H22 | Mouse hepatoma |
| 4T1 | Breast cancer |
| LL/2 | Lewis lung carcinoma |
| Renca | Kidney carcinoma |
| Hepa 1-6 | Hepatocellular carcinoma |
| 266.6 | Pancreatic acinar neoplasm |
| Hepa1c1c7 | Hepatocellular carcinoma |
| MBT-2 | Bladder transitional cell carcinoma |
| MC38-OVA | Colon carcinoma (Engineered) |
| MC38-hPDL1 | Colon carcinoma (Humanized) |
